Thank you!
Your gift keeps The Millerton News in our towns.

Future of weight loss

More than 40% of Americans are now classified as obese while 75% of adults are either overweight or obese. A new group of drugs called GLP-1 receptor agonists have come on the scene to help in the battle to lose weight. Are they as good as we think?

You may have heard about them or some of their brand names like Zepbound, Wegovy, and Ozempic. The use of these drugs has exploded in popularity to the point where companies like Lilly and Novo Nordisk have had problems keeping up with demand. There is nothing magical about the science behind these drugs. GLP-1 mimics a protein naturally produced by our small intestines. The receptors for these medicines are located across the body. They help us lose weight because receptors in the gastrointestinal tract slow down and send signals to the brain that give us a sense of feeling full.

There are some side effects but nothing too serious for most patients. We are still learning how these medications impact the body. They are currently approved for treating diabetes, obesity, and those with a history of cardiovascular disease in people who are overweight. There are a few drawbacks to these drugs at present.

Typically, GLP-1 agonists are administered as injections in the abdomen, upper arms, outer thighs, or upper buttocks via a syringe and needle or a pre-filled dosing pen. The shots are generally taken once a day or once a week.

For many, this is a big turn-off. Fortunately, you will be able to take tablets soon. The typical weight loss is from 5-15% of body weight over at least 12 months. But GLP-1 is no quick fix. Like exercise, you must stick with it. If you stop taking it, most people regain the weight they lost. And you can’t expect to magically lose weight while you continue to eat all that junk food you get.

The second drawback is the expense. These medications’ list price is around $1,000 a month to $1,400 a month. Without insurance, we are talking $12,000 plus per year for these drugs. Many insurance plans cover some portion of GLP-1 costs, but the extent of coverage can vary significantly. You probably are wondering whether Medicare covers GLP-1 medications. They do for certain medically accepted indications such as heart attack or cardiovascular disease but not for weight management. To qualify, you must have a BMI of 30 or higher, or 27 or higher with comorbidities like high blood pressure, high cholesterol, or type 2 diabetes. They are currently covered through Part D plans.

An entirely new team of individuals, including a retired congressman, a surgeon, and a talk-show host could play pivotal roles in how the government goes about safeguarding America’s health.

Coinsurance amounts are pegged to the list price of drugs. As such, Medicare beneficiaries who qualify could still face monthly costs of $250 to $430 before they reach the annual out-of-pocket drug spending established by the Inflation Reduction Act (IRA). The IRA cap for out-of-pocket expenses were around $3,300 in 2024 and will be $2,000 in 2025. Most retirees living on modest incomes would still find the cost of GLP-1 prohibitive.

In November 2024, the Biden Administration proposed that Medicare and Medicaid cover obesity medications. In doing so, they sidestepped a twenty-year-old piece of legislation that prevented Medicare from covering drugs for ‘weight loss.’ The new proposal specifies that the drugs would be covered to treat the disease of obesity and prevent related conditions. Those conditions are serious and include diabetes, high blood pressure, cardiovascular disease, sleep apnea, fatty liver disease, and arthritis.

The classification would also mean that every state Medicaid program would be required to cover the drugs starting in 2026. Between the two programs, an additional 7.4 million Americans would gain coverage. The price tag would be high, at least $36 billion over a decade. However, there are more obesity drugs in the pipeline and prices should fall as competition heats up. Starting in 2025, Medicare will also be able to negotiate a lower price for Wegovy as well as many other popular drugs.

As for the future, the costs and usage of GLP-1 medications could change significantly under the second Trump Administration. An entirely new team of individuals, including a retired congressman, a surgeon, and a talk-show host could play pivotal roles in how the government goes about safeguarding America’s health.

Under Robert F. Kennedy, an environmental lawyer, politician, and anti-vaccine organizer, we can expect radically different views and actions in health care, medicine, food safety, and science research. Early indications are that Kennedy, who would run the Department of Health and Human Services, is not a big fan of Ozempic. He does not believe that using popular GLP-1 drugs is ever going to make America healthy again. His remedy would be to provide good food to Americans. He believes that providing three nutritious meals a day to all Americans would solve obesity and diabetes overnight. The problem is that for many Americans the admonition to change your diet, eat less, and exercise more has failed to dent the problem. Why not give the country an avenue that shows a much better chance of success over the long term?



Bill Schmick is a founding partner of Onota Partners, Inc., in the Berkshires.

The views expressed here are not necessarily those of The Millerton News and The News does not support or oppose candidates for public office.

Latest News

Farm & Friends: a holiday market that gives back

The Farm & Friends holiday market returns Nov. 21 and 22, featuring local makers, food producers and seasonal gifts.

Provided

According to PBS, “More than 5 million people have lost their Supplemental Nutrition Assistance Program, or SNAP, benefits since President Trump’s so-called One Big Beautiful Bill passed last year.” Combined with rising costs and new eligibility requirements, these cuts have placed additional pressure on families struggling to make ends meet. As more people turn to food banks and pantries for assistance, local farms are playing an increasingly important role in meeting that need. Hungry Reaper Farm in Morris, for example, supplies food and CSA shares to a variety of nonprofit organizations and schools.

In Dutchess County, The Webatuck Valley Farm Collaborative is working to strengthen the pipeline from farms to foodbanks. Led by Rock Steady Farm, Sweet Freedom Farm and Wildseed Community Farm and Healing Village, the collaborative hopes to double the infrastructure capacity for at least 15 local farms. This will allow them to increase supplies for food pantries and regional schools while expanding the farms’ reach to industrial buyers and distributors. By their estimation, the food hub “will supply and impact 9 school districts, 13 food pantries, and partner with 6 institutional buyers and 8 aggregators and distributors.”

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Under the big top at Full Circus Farm

Under the big top at Full Circus Farm

Miriam Goler and Mark Stonehill with their Haflinger horses, Sunshine and Sandy, at Full Circus Farm in Pine Plains.

L. Tomaino
We share this farm with such amazing human and nonhuman neighbors.
— Mark Stonehill

For Mark Stonehill and Miriam Stonehill Goler, the founder of Full Circus Farm in Pine Plains, farming has always been about more than what comes out of the ground.

“From the very beginning, we’ve envisioned the farm as a place not only for food production, but also merriment and community,” they said.

Keep ReadingShow less
At Ancram Center, community takes center stage
Ancram Center staff and teaching artists after the ceremony.From left to right,Simone Stevens, Sarah Katan, Jeffrey Mousseau, Erin Krom and Chris McCoy.
Provided

At the Ancram Center for the Arts, the stage has been host to numerous award winning professional actors, but it also often belongs to a neighbor with a story to tell. Other times, the performance moves out of the theater altogether, transforming a pond, a field or a corner of town into a stage.

That commitment to bringing theater into the community — and the community into the theater — has earned the Ancram Center the Larry Murray Award for Community Outreach and Support through Theater, one of the Berkshire Theatre Critics Association’s annual Berkie Awards.

Keep ReadingShow less
The Cornwall Whale resurfaces in West Cornwall

The Cornwall Whale is the brain-child of visual and experiential designer Lindsay Stadig.

Provided

There’s something oddly familiar yet intangibly foreign about the Cornwall Whale. It’s not an interiors store, even though there are chairs and furnishings for sale. It’s not an art gallery, though there are paintings and sculptures occupying every corner of the space. It’s not a boutique, even with locally handmade shoes and carefully selected garments. No, The Cornwall Whale is something truly unique in the world of the truly unique.

The enigmatic shop popped up in the early winter of 2025 at the Hughes Memorial Library, right on the bank of the Housatonic River in West Cornwall. It is the brain-child of visual and experiential designer Lindsay Stadig.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.